The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy ... there may be additional dementia risk reduction for semaglutide, according to ...

Gabapentin is routinely used to treat nerve pain and restless leg syndrome, but it might be riskier to our brain health than ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Groundbreaking new research has found that the popular weight loss drug Ozempic could also reduce the risk of developing Alzheimer’s disease. GLP 1 medications - the group of drugs behind ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. ... Pharmacist cautions against self-medicating with ozempic for dementia risk reduction.

It could also play a role in reducing the risk of dementia.We asked the experts. Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 ... The reduction in food preoccupation ...

Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. Patients who took Ozempic also saw an 18% reduction in nicotine dependence compared ...